RU2005130647A - НОВЫЕ ПРОИЗВОДНЫЕ АМИНОПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGIuR5 - Google Patents
НОВЫЕ ПРОИЗВОДНЫЕ АМИНОПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGIuR5 Download PDFInfo
- Publication number
- RU2005130647A RU2005130647A RU2005130647/04A RU2005130647A RU2005130647A RU 2005130647 A RU2005130647 A RU 2005130647A RU 2005130647/04 A RU2005130647/04 A RU 2005130647/04A RU 2005130647 A RU2005130647 A RU 2005130647A RU 2005130647 A RU2005130647 A RU 2005130647A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- amine
- methyl
- halogen
- formula
- Prior art date
Links
- 150000003927 aminopyridines Chemical class 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 230000002265 prevention Effects 0.000 claims abstract 5
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims abstract 3
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims abstract 3
- 208000015114 central nervous system disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000005026 carboxyaryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- RJQPFKTXLGKANB-UHFFFAOYSA-N 4-chloro-6-methyl-2-(2-phenylethynyl)pyridin-3-amine Chemical compound CC1=CC(Cl)=C(N)C(C#CC=2C=CC=CC=2)=N1 RJQPFKTXLGKANB-UHFFFAOYSA-N 0.000 claims 3
- 206010012335 Dependence Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- -1 aryl-C 1 -C 6 -alkyl Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000003227 neuromodulating effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- IOSCMJDURLQTGT-UHFFFAOYSA-N 2-[2-(3,5-difluorophenyl)ethynyl]-6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C(C#CC=2C=C(F)C=C(F)C=2)=N1 IOSCMJDURLQTGT-UHFFFAOYSA-N 0.000 claims 1
- OEJKHVWZFQTQNL-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethynyl]-4,6-dimethylpyridin-3-amine Chemical compound CC1=CC(C)=C(N)C(C#CC=2C=C(Cl)C=CC=2)=N1 OEJKHVWZFQTQNL-UHFFFAOYSA-N 0.000 claims 1
- QQOXDHYFAFCOGI-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethynyl]-6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C(C#CC=2C=C(Cl)C=CC=2)=N1 QQOXDHYFAFCOGI-UHFFFAOYSA-N 0.000 claims 1
- SMDCSNKFFKCUDO-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C(C#CC=2C=C(F)C=CC=2)=N1 SMDCSNKFFKCUDO-UHFFFAOYSA-N 0.000 claims 1
- QCJAHNVWWBKYPB-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethynyl]-6-methylpyridin-3-amine Chemical compound COC1=CC=CC(C#CC=2C(=CC=C(C)N=2)N)=C1 QCJAHNVWWBKYPB-UHFFFAOYSA-N 0.000 claims 1
- PMSIVLUKLPUCEB-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethynyl]-6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C(C#CC=2C=CC(F)=CC=2)=N1 PMSIVLUKLPUCEB-UHFFFAOYSA-N 0.000 claims 1
- QTJXWVKVUZKWNF-UHFFFAOYSA-N 2-[2-(5-fluoropyridin-3-yl)ethynyl]-6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C(C#CC=2C=C(F)C=NC=2)=N1 QTJXWVKVUZKWNF-UHFFFAOYSA-N 0.000 claims 1
- BCOVWXGMAVOKNR-UHFFFAOYSA-N 6-methyl-2-(2-phenylethynyl)pyridin-3-amine Chemical compound CC1=CC=C(N)C(C#CC=2C=CC=CC=2)=N1 BCOVWXGMAVOKNR-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010012225 Delirium tremens Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 235000019788 craving Nutrition 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- MEDCLNYIYBERKO-UHFFFAOYSA-N raseglurant Chemical compound CC1=CC(C)=C(N)C(C#CC=2C=C(F)C=CC=2)=N1 MEDCLNYIYBERKO-UHFFFAOYSA-N 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1. Соединение формулы
но исключая 3-амино-4-хлор-6-метил-2-(2-фенилэтинил)пиридин,
где R1 представляет собой метил,
R2 и R3 независимо выбраны из водорода, галогена, нитро, C1-C6-алкила;
R4 представляет собой 
,
R6 и R7, которые могут быть одинаковыми или различными, представляют собой водород или группу формулы: -X-R8, где Х представляет собой =CH-N(R8)2 и R8 представляет собой водород, C1-C6-алкил, галоген-C1-C6-алкил, арил, арил-C1-С6-алкил, гетероарил или гетероарил-C1-С6-алкил;
R5 представляет группу формулы
где R9, R10, R11, R12 и R13 независимо представляют собой водород, галоген, циано, нитро, C1-C6-алкил, галоген-C1-C6-алкил, C1-C6-алкокси, карбокси-C1-C6-алкил или карбоксиарил;
R14 и R15 независимо имеют значения, определенные выше для R9-R13;
или фармацевтически приемлемые соли, гидраты или сольваты таких соединений.
2. Соединение по п.1, имеющее формулу
где R2 и R3 независимо выбраны из водорода, C1-C6-алкила;
R5 представляет группу формулы
где R9, R10, R11, R12 и R13 независимо представляют собой водород, галоген, циано, нитро, C1-C6-алкил, галоген-C1-C6-алкил, C1-C6-алкокси, карбокси-C1-C6-алкил или карбоксиарил;
R14 и R15 независимо имеют значения, определенные выше для R9-R13;
или фармацевтически приемлемые соли, гидраты или сольваты таких соединений.
3. Соединение по п.1 или 2, имеющее формулу
где R2 и R3 независимо выбраны из водорода, С1-С6-алкила;
R9, R10, R11, R12 и R13 независимо представляют собой водород, галоген, циано, нитро, С1-С6-алкил, галоген-С1-С6-алкил, С1-С6-алкокси, карбокси-С1-С6-алкил или карбоксиарил;
или фармацевтически приемлемые соли, гидраты или сольваты таких соединений.
4. Соединение по п.1 или 2, имеющее формулу
где R2 и R3 независимо выбраны из водорода, С1-С6-алкила;
R14 и R15 независимо представляют собой водород, галоген, циано, нитро, С1-С6-алкил, галоген-С1-С6-алкил, С1-С6-алкокси, карбокси-С1-С6-алкил или карбоксиарил;
или фармацевтически приемлемые соли, гидраты или сольваты таких соединений.
5. Соединение по п.1, где указанное соединение выбрано из
(6-метил-2-фенилэтинилпиридин-3-ил)амина
N,N-диметил-N'-(6-метил-2-фенилэтинилпиридин-3-ил)формамидина
(2-(3-фторфенилэтинил)-6-метилпиридин-3-ил)амина
(2-(3-метоксифенилэтинил)-6-метилпиридин-3-ил)амина
(6-метил-2-пиридин-3-илэтинилпиридин-3-ил)амина
(2-(4-фторфенилэтинил)-6-метилпиридин-3-ил)амина
(2-(3,5-дифторфенилэтинил)-6-метилпиридин-3-ил)амина
(2-(5-фторпиридин-3-илэтинил)-6-метилпиридин-3-ил)амина
3-(3-амино-6-метилпиридин-2-илэтинил)бензонитрила
(2-(5-хлорпиридин-3-илэтинил)-6-метилпиридин-3-ил)амина
(2-(3-хлорфенилэтинил)-6-метилпиридин-3-ил)амина
(2-(3-фторфенилэтинил)-4,6-диметилпиридин-3-ил)амина
(2-(3-хлорфенилэтинил)-4,6-диметилпиридин-3-ил)амина
и их фармацевтически приемлемых солей.
6. Фармацевтическая композиция, включающая терапевтически эффективное количество соединения по пп.1-5, и фармацевтически приемлемый носитель и/или эксципиент.
7. Способ лечения или предотвращения состояния у млекопитающего, включая человека, лечение или предотвращение которого находится под воздействием или облегчается нейромодулирующим эффектом антагонистов mGluR5 рецепторов, включающий введение нуждающемуся в таком лечении или предотвращении млекопитающему эффективного количества соединения по пп.1-5.
8. Способ по п.7, в котором указанное состояние представляет собой расстройство центральной нервной системы, выбранное из: устойчивости к веществам или зависимости от них, депрессии, биполярного расстройства, психиатрических заболеваний, таких как психотические расстройства, расстройство в виде дефицита внимания/гиперактивности, болезни Паркинсона, нарушения памяти, болезни Альцгеймера, деменции, белой горячки, нейродегенерации, нейротоксичности, ишемии.
9. Способ по п.7, в котором указанное состояние представляет собой воспалительную или нейропатическую боль, причем соединение по пп.1-5 по существу не проникает в центральную нервную систему.
10. Способ по п.7, в котором указанное состояние представляет собой устойчивость к веществам или зависимость от них, невротическую булимию, невротическую анорексию, тягу к азартным играм, зависимость от курения, сексуальную зависимость, абстиненцию при прекращении приема веществ или навязчиво-компульсивные расстройства.
11. Способ по п.7, в котором указанное состояние представляет собой злоупотребление алкоголем, никотином, кокаином, амфетамином, бензодиазепином, опиатом или алкоголем, или пристрастие к ним.
12. Способ по п.7, в котором указанное состояние представляет собой тревогу, паническое расстройство, фобию, посттравматическое стрессовое расстройство, расстройство генерализованной тревоги, острое стрессовое расстройство.
13. Способ по п.7, в котором указанное состояние представляет собой мигрень.
14. Применение соединения формулы I по пп.1-5 для изготовления лекарственного средства для лечения или предотвращения состояния у млекопитающего, лечение или предотвращение которого находится под воздействием или облегчается нейромодулирующим эффектом антагонистов mGluR5 рецепторов.
15. Фармацевтическая композиция по п.6, где указанным соединением является 3-амино-4-хлор-6-метил-2-(2-фенилэтинил)пиридин.
16. Способ по п.7, где указанным соединением является 3-амино-4-хлор-6-метил-2-(2-фенилэтинил)пиридин.
17. Применение по п.14, где указанным соединением является 3-амино-4-хлор-6-метил-2-(2-фенилэтинил)пиридин.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0304901A GB0304901D0 (en) | 2003-03-04 | 2003-03-04 | Novel aminopyridine derivatives as mGIuR5 antagonists |
| GB0304901.2 | 2003-03-04 | ||
| GB0316430.8 | 2003-07-14 | ||
| GB0316430A GB0316430D0 (en) | 2003-07-14 | 2003-07-14 | Aminopyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005130647A true RU2005130647A (ru) | 2006-04-10 |
| RU2330020C2 RU2330020C2 (ru) | 2008-07-27 |
Family
ID=32964064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005130647/04A RU2330020C2 (ru) | 2003-03-04 | 2004-03-04 | НОВЫЕ ПРОИЗВОДНЫЕ АМИНОПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGIuR5 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7205411B2 (ru) |
| EP (2) | EP2028180A1 (ru) |
| JP (1) | JP2006519251A (ru) |
| AT (1) | ATE415390T1 (ru) |
| AU (1) | AU2004218180B2 (ru) |
| CA (1) | CA2517083A1 (ru) |
| CY (1) | CY1108837T1 (ru) |
| DE (1) | DE602004017966D1 (ru) |
| DK (1) | DK1603877T3 (ru) |
| ES (1) | ES2316968T3 (ru) |
| PL (1) | PL1603877T3 (ru) |
| PT (1) | PT1603877E (ru) |
| RU (1) | RU2330020C2 (ru) |
| SI (1) | SI1603877T1 (ru) |
| UA (1) | UA81464C2 (ru) |
| WO (1) | WO2004078728A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0413605D0 (en) | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| AU2006240217A1 (en) * | 2005-04-22 | 2006-11-02 | Merck & Co., Inc. | Phenyl ethyne compounds |
| WO2007035823A2 (en) * | 2005-09-20 | 2007-03-29 | Molecular Neuroimaging, Llc | Partial mglur5 antagonists and methods of use thereof |
| DE102005062987A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| EP2272509A1 (en) * | 2006-09-11 | 2011-01-12 | Novartis AG | New Uses of metabotropic glutamate receptors |
| CN103561740A (zh) | 2011-03-18 | 2014-02-05 | 诺瓦提斯公司 | 用于帕金森病中多巴胺诱导的运动障碍的α7烟碱性乙酰胆碱受体活化剂和mGluR5拮抗剂的组合 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6028963A (ja) * | 1983-07-27 | 1985-02-14 | Takeda Chem Ind Ltd | 置換ビニル誘導体 |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| DE10009000A1 (de) | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
| NZ525917A (en) | 2000-12-04 | 2005-11-25 | F | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders |
-
2004
- 2004-03-04 RU RU2005130647/04A patent/RU2330020C2/ru not_active IP Right Cessation
- 2004-03-04 WO PCT/IB2004/000745 patent/WO2004078728A1/en active Application Filing
- 2004-03-04 PT PT04717193T patent/PT1603877E/pt unknown
- 2004-03-04 UA UAA200508498A patent/UA81464C2/xx unknown
- 2004-03-04 DE DE602004017966T patent/DE602004017966D1/de not_active Expired - Lifetime
- 2004-03-04 JP JP2006506343A patent/JP2006519251A/ja active Pending
- 2004-03-04 ES ES04717193T patent/ES2316968T3/es not_active Expired - Lifetime
- 2004-03-04 EP EP08018437A patent/EP2028180A1/en not_active Withdrawn
- 2004-03-04 CA CA002517083A patent/CA2517083A1/en not_active Abandoned
- 2004-03-04 AU AU2004218180A patent/AU2004218180B2/en not_active Ceased
- 2004-03-04 DK DK04717193T patent/DK1603877T3/da active
- 2004-03-04 SI SI200431006T patent/SI1603877T1/sl unknown
- 2004-03-04 EP EP04717193A patent/EP1603877B1/en not_active Expired - Lifetime
- 2004-03-04 PL PL04717193T patent/PL1603877T3/pl unknown
- 2004-03-04 AT AT04717193T patent/ATE415390T1/de not_active IP Right Cessation
-
2005
- 2005-09-02 US US11/225,490 patent/US7205411B2/en not_active Expired - Fee Related
-
2007
- 2007-03-13 US US11/717,860 patent/US20080004316A1/en not_active Abandoned
-
2009
- 2009-02-26 CY CY20091100218T patent/CY1108837T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2330020C2 (ru) | 2008-07-27 |
| ATE415390T1 (de) | 2008-12-15 |
| ES2316968T3 (es) | 2009-04-16 |
| US20060030601A1 (en) | 2006-02-09 |
| DK1603877T3 (da) | 2009-03-09 |
| EP1603877A1 (en) | 2005-12-14 |
| AU2004218180A1 (en) | 2004-09-16 |
| UA81464C2 (en) | 2008-01-10 |
| US7205411B2 (en) | 2007-04-17 |
| CA2517083A1 (en) | 2004-09-16 |
| JP2006519251A (ja) | 2006-08-24 |
| EP1603877B1 (en) | 2008-11-26 |
| PL1603877T3 (pl) | 2009-05-29 |
| US20080004316A1 (en) | 2008-01-03 |
| EP2028180A1 (en) | 2009-02-25 |
| DE602004017966D1 (de) | 2009-01-08 |
| CY1108837T1 (el) | 2014-07-02 |
| AU2004218180B2 (en) | 2009-11-12 |
| SI1603877T1 (sl) | 2009-04-30 |
| PT1603877E (pt) | 2009-02-11 |
| WO2004078728A1 (en) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6918088B2 (ja) | Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン | |
| JP6630374B2 (ja) | τリン酸化を阻害する方法 | |
| US6423711B1 (en) | Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands | |
| NO20072833L (no) | Bi- og tricykliske substituterte fenylmetanoner som glycinetransportor I-(Glyt-1)-inhibitorer for behandling av Alzheimers sykdom | |
| NO20072116L (no) | Farmasoytiske forbindelser | |
| RU2006124518A (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| KR20080071562A (ko) | ２-아미노벤즈아미드 유도체 | |
| BRPI0613491A2 (pt) | antagonistas de piperazina-piperidina e agonistas do receptor de 5-ht1a | |
| CZ288944B6 (cs) | Derivát 5H-thiazolo[3,2-a]pyrimidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje | |
| US20020156280A1 (en) | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | |
| BRPI0409110A (pt) | derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer | |
| KR100602929B1 (ko) | 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체 | |
| RU98112237A (ru) | Новые производные индол-2,3-дион-3-оксима | |
| CZ299765B6 (cs) | Benzofurazanová sloucenina, její použití a farmaceutická kompozice ji obsahující | |
| CA3149989A1 (en) | Methods of treating epilepsy using the same | |
| CN103717593A (zh) | 调节激酶的组合物和方法 | |
| DK171133B1 (da) | 1-Pyridyl- eller -pyrimidyl-4-substitueret alkyl-piperaziner eller -homopiperaziner, fremstilling af disse, samt farmaceutiske præparater indeholdende disse | |
| JPH09506103A (ja) | ニューロキニンａ拮抗剤としての二環式複素環化合物 | |
| SK2162000A3 (en) | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands | |
| JP2001527045A (ja) | シノプス反応を高めるベンゾキサジン化合物 | |
| AU2020284606B2 (en) | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2005130647A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ АМИНОПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGIuR5 | |
| RU2007125659A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
| MXPA02011464A (es) | Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1. | |
| EA006203B1 (ru) | Гетероарильные производные, их получение и применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110305 |